MedTrace Logo

Transcranial Magnetic Stimulation in Treatment of Attention Deficit/Hyperactivity Disorders

NCT01618110 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-06-19

No results posted yet for this study

Summary

* ADHD is one of the most common psychiatric disorders.
* While most of the attention is directed towards youth, 60% continue to suffer symptoms into adult life.
* Current treatment is effective, but 30% suffer side effects that lowers QOL, and 20% are non-responders.
* Known mechanism of pathophysiology includes hypoactive dopaminergic system, especially at right PFC.
* It is this study hypothesis that by stimulating the right PFC by TMS, it will be possible to alleviate ADHD symptoms.
* A 10 sessions of treatment will by applied on a randomly allocated group of patients, diagnosed with ADHD, in a 2:1 ratio: The first group will receive an actual TMS treatment, and the second group will receive a sham treatment.
* Improvement of objective and subjective ADHD scale will be examined.

Conditions

  • Attention Deficit/Hyperactivity Disorder

Interventions

DEVICE

Transcranial Magnetic Stimulation (Magstim, Rapid)

Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.

OTHER

Placebo Treatment

Sham coil (minimal magnetic field, same noise and feeling)

Sponsors & Collaborators

  • Shalvata Mental Health Center

    lead OTHER

Principal Investigators

  • Yuval Bloch, MD · Shalvata MHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01618110 on ClinicalTrials.gov